Best Stocks To Buy

In the last two issues of December, I picked several U.S. and Canadian stocks that I felt would do well in 2014. All were previous IWB recommendations.

To close out this series, let's look overseas. Here are two international stocks that I like for the coming year. These trade as ADRs in New York.

Baidu Inc. (BIDU). This is the Chinese equivalent of Google which obviously makes it a very large company with great growth potential. The stock was originally recommended by contributing editor Glenn Rogers in February 2011 at $128.80 (figures in U.S. dollars). It has been extremely volatile, falling to as low as $82.98 last April. But it has been on a tear since mid-summer, closing on Friday at $175.28. That's just short of its 52-week high of $181.25, reached on Dec. 11.

Glenn Rogers last updated the stock as a Buy on Oct. 21 at $165.91, citing the company's strong financial performance and growth potential. Shortly thereafter, the company issued some mixed third-quarter financial results. Total revenue was up 42.3% to almost $1.5 billion. However, most of that was absorbed in higher expenses; profit was ahead only 1.2% to $545.4 million.

Top 5 Tech Companies To Watch In Right Now: Taylor Capital Group Inc.(TAYC)

Taylor Capital Group, Inc. operates as the bank holding company for Cole Taylor Bank that provides a range of commercial banking products and services primarily to closely-held commercial customers and their owner operators in the Chicago area. It offers various deposit products, including checking, savings, and money market accounts, as well as time deposits, and other deposit and credit services to commercial clients and community-based customers, including individuals and small local businesses. The company?s commercial lending activities primarily consist of providing loans for working capital and business expansion or acquisition; owner-occupied commercial real estate financing; revolving lines of credit; and stand-by and commercial letters of credit. It also originates and sells mortgage loans. In addition, the company provides treasury cash management services, including repurchase agreements, Internet balance reporting, remote deposit capture, positive pay, automa ted clearing house products, imaged lock-box processing, controlled disbursement, and account reconciliation services to commercial clients; and investment management and brokerage services. Further, it offers asset-based financing, including revolving lines of credit supported by receivables and inventory; and term loans supported by equipment and real estate. The company?s target commercial lending customers include businesses engaged in various industries, such as manufacturing, wholesale and retail distribution, transportation, construction contracting, and professional services. It operates through nine banking centers in the Chicago area. The company was founded in 1929 and is headquartered in Rosemont, Illinois.

Advisors' Opinion:

• [By Rich Duprey]

  Looking to expand its banking business in the Windy City, MB Financial (NASDAQ: MBFI  ) jointly announced with Taylor Capital (NASDAQ: TAYC  ) that it was buying the�holding company of�Cole Taylor�Bank, a Chicago-based commercial bank with $5.9 billion in assets, $3.3 billion in loans, and $3.7 billion in deposits.

• [By Sean Williams]

  What: Shares of Taylor Capital (NASDAQ: TAYC  ) , the holding company of Cole Taylor Bank, a commercial and consumer lending and financial services company located in the Chicago area, skyrocketed as much as 22% after agreeing to be purchased by MB Financial (NASDAQ: MBFI  ) .

• [By Rich Duprey]

  Commercial banking concern Taylor Capital Group (NASDAQ: TAYC  ) announced yesterday its third-quarter dividend of $0.50 per share on its�Series A perpetual non-cumulative preferred stock, which trades on the Nasdaq exchange under the symbol TAYCO.

Best Stocks To Buy: United States Brent Oil Fund LP (BNO)

United States Brent Oil Fund, LP (USBO) is a commodity pool. USBO is focused on issuing units that may be purchased and sold on the NYSE Arca, Inc. The investment objective of USBO is for the daily changes in percentage terms of its units��per unit net asset value (NAV) to reflect the daily changes in percentage terms of the spot price of Brent crude oil, as measured by the daily changes in the price of the futures contract for Brent crude oil traded on the ICE Futures Exchange (the ICE Futures).

The investment portfolio of USBO will consist primarily of investments in futures contracts for crude oil, heating oil, gasoline, natural gas and other petroleum-based fuels that are traded on the ICE Futures, New York Mercantile Exchange (the NYMEX) or other United States and foreign exchanges (collectively, Futures Contracts). USBO may also take positions in other crude oil-related investments, such as cash-settled options on Futures Contracts, forward contracts for oil, cleared swap contracts and non-exchange traded (over-the-counter) transactions that are based on the price of crude oil, other petroleum-based fuels, Futures Contracts and indices based on the foregoing (collectively, Other Crude Oil-Related Investments).

Advisors' Opinion:

• [By Dr. Kent Moors]

  It's time to pull back a bit on exchange-traded fund (ETF) holdings allowing moves playing the WTI-Brent crude pricing spread. I have suggested previously the two primary plays here are PowerShares DB Energy (NYSE Arca: DBE) and United States Brent Oil Fund (NYSE Arca: BNO).

• [By Aaron Levitt]

  As we said before, the Iranian deal doesn�� actually add any new supplies back into marketplace for quite some time. With oil demand starting to move ahead as the global economy is beginning to return to normalcy, Brent prices should grind their way upwards. That makes the United States Brent Oil (BNO) a prime play.

• [By Dan Caplinger]

  How to invest
  If those trends persist, then it could eventually solve the problem that United States Oil Fund has had in underperforming the spot price of crude. Given Brent's stronger backwardation trend, United States Brent Oil Fund (NYSEMKT: BNO  ) might be the better oil ETF to choose.

Best Stocks To Buy: Enertopia Corp (ENRT)

Enertopia Corp (Enertopia), incorporated on November 24, 2004, is engaged in medicinal marijuana business. The Company is diverse in its pursuit of business opportunities in several sectors, including: Medicinal Marijuana, Oil and Gas, Solar PV (Photovoltaic), Solar Thermal (Hot Water), Energy Retrofits and Recovery, and Solar powered Filtered Drinking Water.

The Company no longer has any material oil and gas resources. The Company operates in two segments: renewable energy, and mining exploration and developments, which are managed separately based on fundamental differences in their operations nature.

Advisors' Opinion:

• [By Peter Graham]

  What�� the Catch With Lexaria Corp? According to various disclosures, a transaction or transactions of $1k has or will occur to mention Lexaria Corp in various investment newsletters. Last Friday, Lexaria Corp announced it had closed its Private Placement financing announced on March 5 for gross proceeds of $1,272,000 ��higher than the originally announced $960,000 figure due to ��verwhelming demand.��Lexaria Corp will issue 10,600,000 common shares at US$0.12 and 10,600,000 full warrants that expire on September 21, 2016 with an exercise price of US$0.25. However, the company may also accelerate the expiry date of the warrants if the stock price trades above CAD$0.40 cents for 20 consecutive days at any time after 6 months and one day has elapsed. Otherwise and in early March, Lexaria Corp reported that its board of directors had decided to make a strategic entry into the medical marijuana business by way of an ��mportant Joint Venture��with Enertopia Corp (OTCQB: ENRT). Under the terms of the Agreement, Lexaria Corp had agreed to pay Enertopia 1 million restricted common shares in return for Enertopia's participation plus 500,000 restricted common shares ENRT�� Chairman in return for his participation on the Lexaria Advisory Board. Following the issuance of these shares, Lexaria Corp will have a total of 18,431,452 shares issued and outstanding and 21,256,452 shares fully diluted. A quick look at Lexaria Corp�� financials reveals revenues of $160k (most recent reported quarter), $241k, $251k and $253k for the past four quarters along with net losses of $102k (most recent reported quarter), $126k, $58k and $48k. At the end of last January, Lexaria Corp had $66k in cash to cover $1,415k in current liabilities and $59k in other liabilities. So aside from the income statement, investors might want to look more closely at Lexaria Corp�� financing terms.

Best Stocks To Buy: Intercept Minerals Ltd (UMG)

Intercept Minerals Ltd. is engaged in gold and base metals exploration. The Company focuses on Ianna Gold Project in Guyana South America. The Ianna Joint Venture encompassed mineral rights over a 54 square kilometer suite of contiguous mining permits, which are centred over the Ianna/Yakishuru gold mining district located within the well-known Guiana shield region of Guyana. The Box Hole lead/zinc project is located in the Northern Territory, Australia. The Adnera project (alaskite hosted) is located approximately 200 kilometer north of Alice Springs in the Northern Territory. The Millionaires Well Tungsten project is located about 200 kilometer north of Alice Springs. The bauxite project is located in the north east region of Melville Island within the Tiwi Islands north of Darwin. Advisors' Opinion:

• [By Vera Yuan]

  Vivendi SA (0.4%) (VIV) (VIV - $24.47 - NYSE) is a French media and telecommunications holding company in the late stages of a decade long transition. In April 2014, the company announced it had reached an agreement to sell its French wireless operation, SFR, to French cable operator Numericable. Over the last year, the company also sold most of its 62% stake in Activision Blizzard and reached an agreement to sell its entire 53% stake in Maroc Telecom SA. After closing the SFR sale in early 2015, Vivendi will be a more focused media firm, consisting of Canal+ (a Francophone focused pay television network owner and distributor), Universal Music Group (UMG), the number one recording music company and number two music publishing entity in the world, and GVT, a fast growing Brazilian broadband and pay television provider. We expect GVT to eventually be sold and would not dismiss the possibility of a breakup of Canal+ and UMG. While operating conditions have been challenging in most of Vivendi�� businesses, it appears their trajectory is finally turning more positive and should be supported by a healthier balance sheet after the SFR, Activision and Maroc disposals.From Mario Gabelli (Trades, Portfolio)�� The Gabelli Asset Fund Second Quarter 2014 Shareholder Commentary.Also check out: Mario Gabelli Undervalued Stocks Mario Gabelli Top Growth Companies Mario Gabelli High Yield stocks, and Stocks that Mario Gabelli keeps buying Currently 0.00/512345

  Rating: 0.0/5 (0 votes)

Best Stocks To Buy: PIMCO 1-5 Year US TIPS Index Exchange-Traded Fund (STPZ)

PIMCO 1-5 Year US TIPS Index ETF, formerly Pimco 1-5 Year U.S. TIPS Index Fund, is an exchange traded fund (ETF) designed to capture the returns of the shorter maturity subset of the Treasury Inflation-Protected Securities (TIPS) market by tracking The BofA Merrill Lynch 1-5 Year US Inflation-Linked Treasury Index. The BofA Merrill Lynch 1-5 Year US Inflation-Linked Treasury Index is an unmanaged index comprised of the United States Treasury Inflation Protected Securities with at least $1 billion in outstanding face value and a remaining term to final maturity of at least one year and less than five years. Advisors' Opinion:

• [By Benjamin Shepherd]

  While there are several exchange-traded funds (ETFs) devoted to TIPS, my favorite is PIMCO 1-5 Year US TIPS Index (NYSE: STPZ).

  This ETF has one of the lowest durations of any of the TIPS funds at 2.7 years, so it won’t take much of a ding based on shifting interest rates.

Best Stocks To Buy: XOMA Ltd.(XOMA)

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcet?s uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.

Advisors' Opinion:

• [By Lisa Levin]

  XOMA (NASDAQ: XOMA) shares gained 7.55% to $4.70 in the pre-market session on encouraging Phase 2 Gevokizumab results.

  Central European Media Enterprises (NASDAQ: CETV) soared 5.67% to $2.98 in the pre-market trading. Central European Media shares have tumbled 48.07% over the past 52 weeks, while the S&P 500 index has gained 23.52% in the same period.

• [By Ben Fox Rubin]

  Xoma Corp.(XOMA) announced it plans to sell shares of its common stock, though it didn’t say how many. The drug developer recently had about 93.1 million shares outstanding, according to FactSet. Shares fell 8.3% to $5.19 premarket.